Clinical Trial Update: QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir [Phase 4]

View source ↗

Summary

A Phase 4 study from Massachusetts General Hospital evaluated 4 weeks of glecaprevir/pibrentasvir to eradicate Hepatitis C in patients undergoing renal transpla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Hepatitis C

Drugs mentioned

• Glecaprevir/pibrentasvir (Mavyret) (glecaprevir/pibrentasvir)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Kidney Failure, Hepatitis C | Phase 4 | Status: TERMINATED | Results posted: 2024-12-03